Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-14T08:15:29.122Z Has data issue: false hasContentIssue false
  • English
  • Français

Tobacco smoking and mental illness: important considerations

Published online by Cambridge University Press:  13 June 2014

Sabina Feeney  and
Brian Hallahan
Sabina Feeney
Affiliation:
Department of Psychiatry, Roscommon County Hospital, Roscommon Brian Hallahan
Brian Hallahan*
Affiliation:
Department of Psychiatry, Roscommon County Hospital, Roscommon and Honorary Research Fellow, Clinical Science Institute, National University of Ireland, Galway, Galway
*
*Correspondence Email: brian.hallahan@nuigalway.ie
Get access Rights & Permissions [Opens in a new window]

Extract

Tobacco smoking is a contributory factor in the death of 50% of individuals who are regular or heavy smokers (The Office of Tobacco Control Ireland defines a regular smoker as someone who smokes 11-20 per day and a heavy smoker as someone who smokes 21 or more cigarettes per day). The World Health Organisation (WHO) regards tobacco smoking as the leading preventable cause of death worldwide. In Ireland, approximately 750,000 people smoke tobacco regularly (23.5% of the population) with 7,000 Irish people dying annually from smoking-related causes. Although there are no exact figures for prevalence rates of smoking in individuals with mental illness in Ireland, international studies unequivocally state that the prevalence of smoking is significantly higher in those with mental illness, with greater nicotine intake and increased prevalence of nicotine dependence also reported. Furthermore people with mental illness experience greater withdrawal symptoms and have lower cessation rates when attempting to stop smoking compared to the general population.

Type
CPD
Information
Irish Journal of Psychological Medicine , Volume 28 , Issue 1 , March 2011 , pp. i - v
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Office of Tobacco Control Ireland. http://www.otc.ie/research.aspGoogle Scholar
2.World Health Organisation. WHO report on the global tobacco epidemic 2008: the MPOWER package. Geneva, World Health Organisation, 2008 (http://www.who.int/tobacco/mpower/en/index.html)Google Scholar
3.Piasecki, M, Newhouse, PA. Nicotine in Psychiatry: Psychopathology and emerging therapeutics. Washington Psychiatric Press Inc. 2000.Google Scholar
4.Lasser, K, Boyd, JW, Woodlander, S, et al.Smoking and Mental illness. A population –based prevalence study. JAMA 2000; 284: 2606–610.CrossRefGoogle ScholarPubMed
5.John, U, Meyer, C, Rumpf, H, et al.Smoking, nicotine dependence and psychiatric co morbidity, a population based study including smoking cessation rates after three years. Drug Alcohol Depend 2004; 76: 287–295.CrossRefGoogle ScholarPubMed
6.de Leon, J, Diaz, FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviours. Schizophr Res 2005; 75: 35–57.Google Scholar
7.Breslau, N, Novac, SP, Kessler, RC. Psychiatric disorders and stages of smoking. Biol Psychiatry 2004; 55: 69–76.CrossRefGoogle ScholarPubMed
8.Poirer, M, Canceil, O, Bayle, F. Prevalence of smoking in psychiatric. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 529–537.CrossRefGoogle Scholar
9.Breslau, N, Kilbey, M, Andreski, P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiological study of young adults. Am J Psychiatry 1992; 149: 464–469.Google Scholar
10.Ismail, K, Sloggett, A, De Stavola, B. Do common mental disorders increase cigarette smoking? Results from five waves of a population-based cohort study. Am J Epidemiol 2000; 152: 651–657.CrossRefGoogle Scholar
11.Glassman, AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993; 150: 546–53.Google ScholarPubMed
12.Meltzer, H, Gill, B, Petticrew, Met al.Economic activity and social functioning of adults with psychiatric disorders (OPCS surveys of psychiatric disorders of Great Britain report 3) London; HMS; 1995.Google Scholar
13.Metzler, H, Gill, B, Petticrew, Met al.Economic activity and social functioning of residents with psychiatric disorders (OPSC Surveys of Psychiatric Morbidity in Great Britain Report 6). London; HMS; 1996.Google Scholar
14.Gill, B, Meltzer, H, Hinds, Ket al.Psychiatric morbidity among homeless people (OPSC Surveys of Psychiatric Morbidity in Great Britian. Report 7). London; HMS; 1996.Google Scholar
15.Solty, H, Crockford, D, White, WDet al.Cigarette Smoking, Nicotine dependence and motivation for smoking cessation in psychiatric inpatients. Can J Psychiatry 2009; 54: 36–45CrossRefGoogle ScholarPubMed
16.de Leon, J, Badvand, M, Canuso, Cet al.Schizophrenia and smoking: an epidemiological study. Am J Psychiatry 1995; 152: 453–455.Google Scholar
17.Ziedonis, D, Hitsmann, B, Beckham, JCet al.Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health Report. Nicotine Tobacco Res 2008; 10: 1691–1715.CrossRefGoogle ScholarPubMed
18.Goodwin, R, Hamilton, SP. Cigarette Smoking and Panic: the role of neuroticism. Am J Psychiatry 2002; 159: 1208–1213.CrossRefGoogle ScholarPubMed
19.Rasmusson, AM, Picciotto, MR, Krishnan-Sarin, S. Smoking as a complex but critical co-variate in neurobiological studies of post-traumatic stress disorder: a review. J Psychopharmacol 2006; 20: 693–707.CrossRefGoogle Scholar
20.Leyro, TM, Zvolesky, MJ, Vujanovic, AA, Bernstein, A. Anxiety sensitivity and smoking motives and outcome expectations among adult daily smokers: replication and extension. Nicotine Tob Res 2008; 10: 985–994.CrossRefGoogle ScholarPubMed
21.Audrain-McGovern, J, Lerman, C, Wileyto, EPet al.Interacting effects of genetic predisposition and depression on adolescent smoking progression. Am J Psychiatry 2004; 161: 1224–1230.CrossRefGoogle ScholarPubMed
22.Perkins, KA, Lerman, C, Grottenthaler, A, et al.Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol 2008; 19: 641–649.CrossRefGoogle ScholarPubMed
23.Lerman, C, Caporoso, N, Main, D, et al.Depression and self medication with nicotine: the modifying influence of the dopamine D4 receptor gene. Health Psychol 1998; 17: 56–62.CrossRefGoogle ScholarPubMed
24.Doran, N, Mc Chargue, D, Spring, B, et al.Effect of nicotine on negative mood among more impulsive smokers. Exp Clin Psychopharm 2006; 14: 287–295.CrossRefGoogle ScholarPubMed
25.Lerman, C, Wiley, EP, Patterson, F, et al.The functional mu-opioid receptor (oprmi) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics 2004; 4: 184–192.CrossRefGoogle Scholar
26.Ritt-Olson, , Unger, J, Valente, T, et al.Exploring peers as a mediator of the association between depression and smoking in young adolescents. Subst Use Misuse 2005; 40: 77–98.CrossRefGoogle ScholarPubMed
27.Sacco, KA, Termine, A, Seyal, A, et al.Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005; 62: 649–59.CrossRefGoogle ScholarPubMed
28.Smith, RC. Effects of nicotine spray on cognitive function in schizophrenia. Neuropsychopharmacology 2006; 31: 637–59.CrossRefGoogle ScholarPubMed
29.Forchuk, C, Norman, R, Malla, A, et al.Schizophrenia and the motivation for smoking. Perspect Psychiatr care 2002; 38: 41–49.CrossRefGoogle ScholarPubMed
30.Haustein, KO, Haffner, S, Woodcock, BG. A review of the pharmacology and psychopharmacological aspects of smoking and smoking cessation in psychiatric patients. Int J Clin Pharmacol Therapy 2002; 40: 404–418.CrossRefGoogle ScholarPubMed
31.Doll, R, Peto, R, Boreham, J, et al.Mortality in relation to smoking: 50 years observation on British male doctors. BMJ 2004; 328: 745.CrossRefGoogle Scholar
32.Irish Cancer Society. www.irishcancer.ieGoogle Scholar
33.Spiro, SG, Silvestri, GA. Primary malignant growths of the lung and bronchi. Am J Respir Crit Care 2005; 172: 523–529.CrossRefGoogle Scholar
34.Kuper, H, Boffetta, P, Adami, HO. Tobacco use and cancer causation, association by tumour type. J Intern Med 2002; 252: 206–224.CrossRefGoogle ScholarPubMed
35.Fachinetti, F, Amadei, F, Geppetti, P, et al.Beta-unsaturated aldehydes in cigarette smoke, release inflammatory mediators from human macrophages. Am J Respir Cell Mol Biol 2007; 37: 617–623.CrossRefGoogle Scholar
36. Heart disease prevention- smoking and cardiovascular disease. https://www.healthsystem.virginia.edu/UVA 2009Google Scholar
37.US Department of Health and Human Services. The health consequences of smoking: a report of the surgeon general. Washington D.C. USA, 2004.Google Scholar
38.Bacher, I, Rabin, R, Woznica, A, et al.Nicotinic Receptor Mechanisms in Neuropsychiatric Disorders: Therapeutic implications. Primary Psychiatry 2010; 17: 35–41.Google Scholar
39.Le Houezec, JL. Nicotine abused substance and therapeutic agent. J Psychiatry Neurosci 1998; 23: 95–108.Google ScholarPubMed
40.George, TP, Vessicchio, JC. Nicotine addiction and other psychiatric disorders. Psychiatric Times. 2001; 18: 39–42.Google Scholar
41.Picciotti, MR, Brunzell, DH, Caldarone, BJ. Neuroreport 2002; 13: 1097–1106.CrossRefGoogle Scholar
42.Weinberger, A H, Creeden, BS, Sacco, KAet al.Neurocognitive Effects of nicotine and tobacco in individuals with Schizophrenia. J Dual Diag 2007; 61–77.CrossRefGoogle Scholar
43.Levin, ED, Connors, CK, Silva, D, et al.Effects of chronic nicotine and methylphenidate in adults with attention deficit hyperactivity disorder. Exp Clin Psychopharmacology 2001; 9: 83–90.CrossRefGoogle ScholarPubMed
44.Levin, ED, Connors, CK, Sparrow, E, et al.Nicotine effects on adults with Attention-Deficit Hyperactivity Disorder. Pyschopharmacology 1996; 123: 55–63.CrossRefGoogle ScholarPubMed
45.Morens, DM, Grandinetti, A, Reed, D, et al.Cigarette smoking and protection from Parkinson's Disease: false association or etiological clue? Am Acad Neurology; 1995; 45: 1041–51.CrossRefGoogle ScholarPubMed
46.Jarvik, A, Murray, E. Beneficial effects of nicotine. Br J Addict. 1991; 86: 571–575.CrossRefGoogle ScholarPubMed
47.Kalman, D, Morissette, SB, George, TP. Co-morbidity of smoking in patients with psychiatric substance use disorders. Am J Addict. 2005; 14: 106–123.CrossRefGoogle ScholarPubMed
48.Spring, B, Cook, JW, Appelhans, B, et al.Nicotine effects on affective response in cigarette smokers. Psychopharmacology 2008; 196: 461–471.CrossRefGoogle Scholar
49.Olincy, A, Harris, JG, Lynn, L, et al.Proof of concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630–638.CrossRefGoogle ScholarPubMed
50.Adler, LE, Hoffer, LD, Wiser, A, et al.Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993; 150: 1856–1861.Google ScholarPubMed
51.Wilens, TE, Biederman, J, Spencer, TJ, et al.A pilot controlled clinical trial of ABT-418, a cholinergic agonist in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156: 1931–1937.CrossRefGoogle ScholarPubMed
52.Gentry, C, Lucas, RJ. Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Discord 2002; 1: 359–385.CrossRefGoogle ScholarPubMed
53.Hong, DP, Fink, AL, Uversky, VN. Smoking and Parkinson's: Does nicotine affect [alpha]-synuclein fibrillation? Biochim Biophys Acta 2009; 1794: 282–90.CrossRefGoogle ScholarPubMed
54.Newhouse, PA, Sunderland, T, Tariot, PN, et al.Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl) 1988; 95: 171–175.CrossRefGoogle ScholarPubMed
55.Silver, A, Shytle, RD, Phillpp, MK, et al.Transdermal nicotine and haloperidol in Tourettes disorder: a double blind placebo-controlled study. J Clin Psychiatry. 2001; 62: 707–714.CrossRefGoogle ScholarPubMed
56.Miller, LG. Recent Developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin Pharmacokinet 1989; 17: 90–108CrossRefGoogle Scholar
57.Desai, HD, Seabolt, J, Jann, MW. Smoking in patients receiving psychotropic medications a pharmacokinetic perspective. CNS Drugs 2001; 15: 469–494.CrossRefGoogle ScholarPubMed
58.Lyon, ER. A Review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv 1999; 50: 1346–1350.CrossRefGoogle ScholarPubMed
59.Haring, C, Fleischacker, WW, Schett, P, et al.Influence of patient related variables on clozapine plasma levels. Am J Psychiatry 1990; 147: 1471–1475.Google ScholarPubMed
60.Haring, C, Meise, U, Humpel, C, et al.Dose related plasma levels of clozapine influence of smoking behaviour, sex and age. Psychopharmacology. 1989; 99(suppl): 538–540.CrossRefGoogle ScholarPubMed
61.Carillo, JA, Herraiz, AG, Ramos, SI, et al.Role of the smoking induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119–127.CrossRefGoogle Scholar
62.Ereshefsky, L, Saklad, SR, Jann, MW, et al.Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985; 20: 329–332.CrossRefGoogle ScholarPubMed
63.Jann, MW, Sacklad, SR, Ereshefsky, L, et al.Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986; 90: 468–470.CrossRefGoogle ScholarPubMed
64.Shimoda, K, Someya, T, Morita, S, et al.Lower levels of Haloperidol in smoking than non smoking schizophrenic patients. Am J Psychiatry 1986; 90: 468–470.Google Scholar
65. Eli Lilly and company limited. Cymbalta. http://emc.medicines.org.uk/.2006Google Scholar
66.Grasmader, K, Verwohlt, PL, Kuhn, KU, et al.Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004; 60: 473–480CrossRefGoogle ScholarPubMed
67.Spigset, O, Carleborg, L, Hedenmalm, K, et al.Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58: 399–403.CrossRefGoogle ScholarPubMed
68.Jochelson, J, Majrowski, B. Clearing the Air: Debating smoke-free policies in psychiatric units. Kings fund, 2006.Google Scholar
69.Campion, J, Checinski, K, Nurse, J. Review of smoking cessation treatments for people with mental illness. APT 2008; 14: 208–216.Google Scholar
70.Kinnunen, T, Doherty, K, Militello, FS, et al.Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol 1996; 64: 791–98.CrossRefGoogle ScholarPubMed
71.Williams, JM, Hughes, JR. Addressing tobacco use in mental health and addiction settings. Psychiatric Annals 2003; 33: 457–466.CrossRefGoogle Scholar
72.Stead, L, Perera, R, Bullen, C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of systematic reviews. 2008 issue1, CD000146. Wiley Interscience, 2008.Google Scholar
73.George, TP, Ziedonis, DM, Feingold, A, et al.Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157: 1835–1842.CrossRefGoogle ScholarPubMed
74.Wang, D, Connock, M, Barton, P, et al.Cut down to quit: with nicotine replacement therapies in smoking cessation: a systematic review. Psychopharmacology 2008; 155: 115–122.Google Scholar
75.Richmond, R, Zwar, N. Review of bupropion for smoking cessation. Drug Alcohol Rev 2003; 22: 203–220.CrossRefGoogle ScholarPubMed
76.Cox, LS, Patten, CA, Niaura, RS, et al.Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 2004; 19: 828–834.CrossRefGoogle ScholarPubMed
77.Evins, AE, Culhane, MA, Birnbaum, A, et al.A 12 week double-blind, placebo controlled study of bupropion SR added to high dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007; 27: 380–386.CrossRefGoogle ScholarPubMed
78.Tsoi, DTPorwal, M, Webster, AC. Interventions for smoking cessation and reduction in individuals with schizophrenia Cochrane Database Syst Rev 2010; CD007253CrossRefGoogle Scholar
79.Woolacott, NF, Jones, L, Forbes, CA, et al.The clinical effectiveness and cost effectiveness of Bupropion (Zyban) and Nicotine replacement therapy for smoking cessation. Health Technol Assess 2002; 6; 1–245.CrossRefGoogle ScholarPubMed
80.Gao, K, Kemp, DE, Ganocy, SJ, et al.Treatment-emergent mania / hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disord 2008; 10: 907–915.CrossRefGoogle ScholarPubMed
81.Davidson, J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50: 256–261.Google ScholarPubMed
82.Alper, K, Schwartz, KAKoltz, RL, Khan, A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007; 62: 345–354CrossRefGoogle ScholarPubMed
83.Settle, EC Jr.Bupropion sustained release: side effect profile J Clin Psychiatry 1998; 59 Suppl 4: 32–36.Google Scholar
84.Aubin, HJTolerability and safety of sustained-release bupropion in the management of smoking cessation (review). Drugs 2002; 62 Suppl 2; 45–52.CrossRefGoogle Scholar
85.Hays, JT, Ebbert, JO. Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc 2003; 78: 1020–1024.CrossRefGoogle ScholarPubMed
86.Rissmiller, DJ, Campo, T. Extended-release bupropion-induced grand mal seizures. J Am Osteopath Assoc 2007; 107: 441–442.Google ScholarPubMed
87.Rosoff, DM. Another case of extended-release bupropion-induced seizures. J Am Osteopath Assoc 2008; 108: 189–190.Google Scholar
88. British Medical Association and Royal Pharmaceutical Society of Great Britain, 2008 British National Formulary. BMJ books & Pharmaceutical press.Google Scholar
89.Kohen, I, Kremen, N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007; 164:1269–1270.CrossRefGoogle Scholar
90.Jorneby, DE, Hays, JT, Rigotti, NA, et al.Efficacy of Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist vs. sustained release bupropion for smoking cessation; a randomised controlled trial. JAMA 2006; 296: 56–63.CrossRefGoogle Scholar
91.Gunnell, D, Irvine, D, Wise, L, et al.Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database BMJ 2009; 339: 3805.Google Scholar
92.Wagena, EJ, Knipchild, P, Zeegers, MP, et al.Should nortriptyline be used as a first line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 2005; 25:218–225.Google Scholar
93.Cinciripini, PM, Tsoh, JY, Weffer, DW, et al.Combined effects of venlafaxine, nicotine replacement, and brief counselling on smoking cessation. Exp Clin Psychopharmacol 2005; 13:282–292.CrossRefGoogle ScholarPubMed
94.Franklin, T, Harper, D, Kampman, K, et al.The GABA B agonist baclofen reduces cigarette consumption in a preliminary double blind placebo controlled smoking reduction study. Drug Alcohol Depend 2009; 103:30–36.CrossRefGoogle Scholar
95.Haas, AL, Munoz, RF, Humfleet, GL, et al.Influences of mood, depression history and treatment modality on outcomes in smoking cessation. J Consult Clin Psychol 2004; 72: 563–570.CrossRefGoogle ScholarPubMed
96.Baker, A, Richmond, R, Haile, M, et al.A randomised controlled trial of a smoking cessation intervention among people with psychotic disorder. Am J Psychiatry 2006; 163: 1934–1942.CrossRefGoogle ScholarPubMed
97.Hall, SM, Munoz, RF, Reus, VIet al.Nicotine, negative affect and depression in smoking cessation. J Consult Clin Psychol 2001; 69: 471–480.Google Scholar
98.Hall, SM, Munoz, RF, Reus, VI, et al.Cognitive-behavioural intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol. 1994; 62: 141–146.CrossRefGoogle Scholar
99.Hall, SM, Munoz, RF, Reus, VI, et al.Nortryptyline and cognitive behavioural therapy in the treatment of cigarette smoking. Arch Gen Psych 1998; 55: 683–691.CrossRefGoogle ScholarPubMed
100.Hall, SM, Munoz, RF, Reus, VI, et al.Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. J Consult Clin Psychol 1996; 64:1003–9.CrossRefGoogle ScholarPubMed
101.Brown, RA, Kahler, CW, Niaura, R, et al.Cognitive behavioural treatment for depression in smoking cessation. J Consult Clin Psychol 2001; 69: 471–480.CrossRefGoogle ScholarPubMed
102.Abbot, NC, Stead, LF, White, AR, Barnes, J. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev 1992; 2: CD001008.Google Scholar
103.White, AR, Rampes, H, Ernst, E. Acupuncture for smoking cessation. Cochrane Database Syst Rev 2000; 2:CD000009.Google Scholar
104. Electronic Medicines Compendium @ http://emc/medicines.org.ukGoogle Scholar
105. National Institute for Clinical Excellence. Brief interventions and referral for smoking cessation in primary care and other settings. Public Health Intervention Guidance No. 10 http://www.nice.org.uk./ph010 2010.Google Scholar
106.http://www.dh.gov.uk/en/policyandguidance/Healthandsocialcaretopics/Tobacco/index.htmNHSStopSmokingServices 2010/2011.Google Scholar
107.Fagerstrom, K, Schneider, NG. Measuring nicotine dependence: A review of the fagerstrom tolerance questionnaire J Beh Med 1989; 12: 159–82.Google Scholar